Latest News for: actinium

Edit

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

PR Newswire 20 Mar 2025
NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc ... Sandesh Seth, Actinium's Chairman and CEO, said, "In 2025 we are reimagining and revitalizing our Actimab-A program leveraging its mutation agnostic, backbone therapy profile.
Edit

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College ...

Victoria Advocate 19 Mar 2025
- Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning ....
Edit

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

PR Newswire 19 Mar 2025
-    Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning ... https.//lifescievents.com/event/actinium-2/.
Edit

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®

PR Newswire 18 Mar 2025
NEW YORK, March 18, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc ... About Actinium Pharmaceuticals, Inc. Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes.
Edit

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or ...

Victoria Advocate 17 Mar 2025
- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy ....
Edit

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

PR Newswire 17 Mar 2025
NEW YORK, March 17, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc ... Actimab-A is a novel targeted radiotherapeutic that uses the Actinium-225 (Ac-225) isotope payload directed against CD33, a marker expressed ubiquitously on AML blasts.
Edit

Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference

PR Newswire 12 Mar 2025
NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN ... Actinium management will be in attendance during the conference and will be available for 1-on-1 meetings on March 17th and 18th.
Edit

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML

PR Newswire 11 Mar 2025
NEW YORK, March 11, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc ... About Actinium Pharmaceuticals, Inc. Actinium is a pioneer in developing targeted radiotherapies intended to meaningfully improve patient outcomes.
Edit

Why Actinium-225 Radioligand Therapy is the Next Step for Non-Responders to Lutetium-177 in Prostate Cancer

The Signal 04 Mar 2025
For these individuals, Actinium-225 radioligand therapy is emerging as a promising alternative that harnesses a different mechanism of action ... The Unique Mechanism of Actinium-225 Radioligand Therapy ... Benefits of Actinium-225..
  • 1
×